News | Timely industry updates for pharma and biotech leaders
WEBPartner Content. pharmaphorum’s news coverage updates daily with the latest pharma and biotech stories, from funding and M&A to regulatory approvals and policy shifts.
The post-COVID face of pharma research - pharmaphorum
WEBManaging COVID’s impact on R&D. Initially, the pandemic caught much of the sector off-guard. A once-in-a-generation event, few could have anticipated the levels of disruptive change COVID-19 brought and that was certainly true for pharma and healthcare. Companies scrambled to implement home-working …
Inside the colourful history of pharma advertising - pharmaphorum
WEBBoots Pharmaceuticals upped the ante in 1983, when it released the first direct-to-consumer TV ad for a prescription drug. Through the TV campaign, Boots Pharmaceuticals publicised the lower price of its pain relief drug Rufen – without directly referencing any specific medical benefits of the product.
Every scientific message has a story. Medical ... - pharmaphorum
WEBMedical communications are in a state of transition. Due to the combined impact of emerging technologies, changing provider preferences, and an evolving post-pandemic world, pharma must navigate new ways to engage providers with …
Patient engagement: from words to actions - pharmaphorum
WEBProviding solutions for patient organisations to be able to engage and maintain a relationship of open dialogues with their stakeholders, in order to break down barriers and identify new approaches to collaboration. Solutions will focus on supporting both parties by creating a framework to follow as plans of what they hope to achieve are developed.
A history of Abbott and AbbVie | pharmaphorum
WEB4 days ago · This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...
How to improve payer engagement - pharmaphorum
WEBBetter payer engagement leads to improved market access. Attitudinal payer segmentation can support pharmaceutical market access strategy by establishing a logic of heterogeneity among payers and providing a framework that enables pharma companies to navigate that diversity. Effective application can support an access strategy that meets the ...
Plotting the way forward on clinical trials - pharmaphorum
WEBResearch sponsors never set out to run 80% white trials. The lack of diversity in clinical trials has arisen from systemic factors. For instance, pharma companies have historically liked to work with the same large, academic medical centres when it comes to trial sites – centres that have well-honed operational procedures, comfortably large patient bases, and an existing, low-risk ...
The rise of the healthcare influencer - pharmaphorum
WEBHowever, 51% trust healthcare patient influencers. Furthermore, 85% of patients trust a pharmaceutical brand or advert if promoted by a POI. For their followers, patient influencers promote positive disease management information, encouraging and normalising positive healthcare behaviour. Patients can feel empowered by learning and engaging ...
SMEs: the next generation of pharma - pharmaphorum
WEBWith this focused support, SMEs will develop the products that will attract the investment they need to grow, rather than sell, and the UK can firmly embed the next generation of this strategic industry sector. The higher-risk areas that big pharma has moved away from could provide the growth opportunity on which SMEs can capitalise.
Skip to content